LQTS: Difference between revisions

LQTS (view source)

Revision as of 02:04, 25 March 2013

1,106 bytes removed , 25 March 2013

m

no edit summary

April

Administrators

144

edits

@@ Line 311: / Line 311: @@
 ===Medication/Other therapies:===
-*Beta-blockers are the cornerstone of therapy in LQTS. Beta-blockers even reduce the risk of sudden death in patients in whom a genetic defect has been found, but no QT prolongation is visible on the ECG and also in LQTS3 patients with bradycardia-associated cardiac events <cite>congenital</cite>
+*Beta-blockers are the cornerstone of therapy in LQTS. Beta-blockers even reduce the risk of sudden death in patients in whom a genetic defect has been found, but no QT prolon
-*[[ICD]] implantation in combination with beta-blockers in LQTS patients with previous cardiac arrest, cardiac [[syncope]] or [[ventricular tachycardia]] while on beta-blockers. ICDs should have pacing possibilities, because arrhythmic episodes are bradycardia-associated in LQTS type 3 and since post-shock pacing is relevant in all other LQTS types.
-*Cardiac sympathetic denervation (LCSD) should be considered in the setting of beta-blocker breakthroughs, intolerance to pharmacotherapy and history of appropriate ICD therapies. Surgically, LCSD involves the resection of the lower two-third of the left stellate ganglion and the left-sided sympathetic chain at the level of T2, T3 and T4.
-==References==
-<biblio>
-#Schwartz2001 pmid=11136691
-#priori pmid=12736279
-#genotype pmid=19926013
-#moss pmid=17470695
-#Alders pmid=20301308
-#probands pmid=22042885
-#QTc pmid=22083145
-#LongQT pmid=20116193
-#Adler pmid=22300664
-#congenital pmid=15851169
-#adenosine pmid=16105845
-</biblio>